Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228429 · ClinicalTrials.gov registry record
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
A clinical trial of Systemic Sclerosis (SSc) and Calcinosis Cutis, sponsored by Yale University.
- Recruiting
- Registry status
- 56
- Enrollment target
- 1
- Study location
NCT07228429 is a study of Systemic Sclerosis (SSc) and Calcinosis Cutis that is actively recruiting participants, run by Yale University. The registered enrollment target is 56 participants, below the 95-participant average among 8 other Systemic Sclerosis (SSc) trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07228429, a study of Systemic Sclerosis (SSc) and Calcinosis Cutis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to develop sensitive radiographic measurement techniques that can be used as outcome measures along with patient-reported outcome instruments in clinical trials of calcinosis cutis treatments, and potentially be used to assess disease course and treatment response in clinical practice. The goal is to test the performance of the software.
Conditions Studied
Interventions
- DRUG Sodium Thiosulfate (STS)
- DRUG Sodium Thiosulfate Injection
Study Locations (1)
Connecticut
- Yale Scleroderma Program - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228429
The ClinicalTrials.gov registry entry for NCT07228429 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 8 other Systemic Sclerosis (SSc) trials with a reported enrollment target (41% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Sclerosis (SSc) appearing as the primary indexed condition, and to 2 interventions - of which Sodium Thiosulfate (STS) is the first listed.
NCT07228429 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07228429 about?
NCT07228429 is a clinical study titled "Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images". The main purpose of this study is to develop sensitive radiographic measurement techniques that can be used as outcome measures along with patient-reported outcome instruments in clinical trials of calcinosis cutis treatments, and potentially be used to assess disease course and treatment response i...
What is the current status of trial NCT07228429?
This trial is currently recruiting. The enrollment target is 56 participants. The study started on 2025-10-14. Estimated completion is 2026-07.
What conditions does trial NCT07228429 study?
This clinical trial studies the following conditions: Systemic Sclerosis (SSc), Calcinosis Cutis.
What interventions are being tested in trial NCT07228429?
The interventions under investigation include: Sodium Thiosulfate (STS) (DRUG), Sodium Thiosulfate Injection (DRUG).
Who is sponsoring clinical trial NCT07228429?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228429 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis (SSc)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
RECRUITING · Phase 2
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
RECRUITING · NA
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
TENS in Scleroderma
RECRUITING · Phase 1
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.